Use of Oral Tranexamic Acid for the Prevention and Treatment of Post-Inflammatory Hyperpigmentation | PracticeUpdate

Use of Oral Tranexamic Acid for the Prevention and Treatment of Post-Inflammatory Hyperpigmentation

Dermatologic Surgery

TAKE-HOME MESSAGE

• Tranexamic acid (TXA) inhibits the conversion of plasminogen to plasmin, thereby resulting in anti-inflammatory, anti-melanogenic, and anti-angiogenic effects. This oral medication has been widely studied as an effective treatment for pigmentary disorders, such as melasma, at low doses. This literature review assessed the use of TXA in the management of post-inflammatory hyperpigmentation (PIH). A TXA dose range from 500 to 750 mg daily for 12 weeks represents the optimal dose and duration for PIH treatment. The use of TXA 325 mg twice daily initiated 2 weeks before and continued for 2 weeks after a laser procedure has been proposed to prevent PIH. Before starting a patient on TXA, thromboembolic and cerebrovascular accident risks should be assessed.
• Although there are no guidelines published for the use of TXA in the treatment of pigmentary disorders, such as PIH, this review of the literature since 2000 suggests that treatment with low doses of TXA may be effective, with minimal side effects, in appropriate patients.

–  Nour Yacoub, MD

https://www.practiceupdate.com/content/use-of-oral-tranexamic-acid-for-the-prevention-and-treatment-of-post-inflammatory-hyperpigmentation/171169

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.